Goran Petrovski, Qatar

Sidra Medicine Pediatrics

Presenter Of 5 Presentations

From MDI to the MiniMed™ 670G System: The Clinical Evidence

Session Name
Session Type
INDUSTRY SESSION
Date
19.02.2020, Wednesday
Session Time
16:15 - 17:45
Channel
Paris
Lecture Time
16:30 - 16:45

From MDI to the MiniMed™ 670G System: The Practice

Session Name
Session Type
INDUSTRY SESSION
Date
19.02.2020, Wednesday
Session Time
16:15 - 17:45
Channel
Paris
Lecture Time
16:45 - 17:45

From MDI to the MiniMed™ 670G System: The Clinical Evidence

Session Type
INDUSTRY SESSION
Date
20.02.2020, Thursday
Session Time
13:00 - 14:30
Channel
Paris
Lecture Time
13:15 - 13:30

From MDI to the MiniMed™ 670G System: The Practice

Session Type
INDUSTRY SESSION
Date
20.02.2020, Thursday
Session Time
13:00 - 14:30
Channel
Paris
Lecture Time
13:30 - 14:30

HOW TO SUCCESSFULLY ON-BOARD PATIENTS WITH TYPE 1 DIABETES FROM MULTIPLE DAILY INJECTION TO HYBRID CLOSED LOOP SYSTEM?

Session Type
ORAL PRESENTATION SESSION
Date
21.02.2020, Friday
Session Time
16:40 - 18:00
Channel
La Paz
Lecture Time
16:40 - 16:50

Abstract

Background and Aims

The aim of this study was to evaluate the effectiveness of a 10-day structured protocol to on-board patients from Multiple Daily Injection (MDI) to the MiniMed 670G system in achieving glycaemic control.

Methods

An open single-arm, single-center, clinical investigation in children aged 7 to 18 years on MDI following a structured protocol: 2 days - selection and introduction; 5 days - Minimed 670G system training (2-hours session in 5 consecutive days with groups of 3 to 5 patients and families); 3 - days in Manual Mode; 84 days in Auto Mode, cumulating in 10 days from MDI to Auto Mode activation of the MiniMed 670G system.

Results

30 children (age 10.24 ± 2.6 years) were enrolled in the study and completed the planned 84 days on Auto Mode. The participants used the sensor for a median of 89% of the time and spent a median of 92 % in Auto Mode. The mean HbA1c decreased from 8.2±1.4% at baseline to 6.7±0.5% at the end of the study phase (p=0.017). Time in Range (70-180mg/dL) increased from 46.9±18.5% at baseline to 75.6±6.9% in Auto Mode (p<0.001). This was achieved while spending 2.8% below 70 mg/dL and without any severe hypoglycemia nor DKA.

Conclusions

Patients with T1D on MDI therapy on-boarded to the MiniMed 670G system, using a structured 10-day protocol, while significantly improved their glycemic control in a safe manner.

Hide